Key facts
- Llusern Scientific’s last known valuation is $6.0M (Sep 2024).
- It has raised $1.6M; the latest was Later Stage VC ($1.0M) in Sep 2024.
- Notable investors include SFC Capital, Development Bank of Wales, Longitude Prize, University of South Wales.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Llusern Scientific
- ·The full record, as it builds
Funding rounds
No funding rounds for Llusern Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Llusern Scientific
Operator of a point-of-care diagnostic system intended to detect urinary tract infections directly from patient samples. The company offers a molecular reader platform with single-use test kits that identify common bacterial pathogens from urine, enabling healthcare providers to perform rapid frontline testing and support timely treatment decisions.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2020
- Employees
- 7
- Website
- llusern.co.uk/
- Ownership
- Privately Held (backing)
Llusern Scientific doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Llusern Scientific shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Llusern Scientific in its N-PORT filings yet. We sweep new filings monthly.